AD Treatment Landscape Examined by FirstWord in New Research Study Published at MarketPublishers.com
09 Jul 2012 • by Natalie Aster
LONDON – What are the current unmet needs and major challenges in AD treatment? What is the most promising late-stage pipeline therapy in disease-modifying development? Which existing first-line therapies for AD face generic erosion in the near future? Where could Johnson & Johnson’s bapineuzumab and Eli Lilly’s solanezumab be positioned in the AD market? How could solanezumab’s different mechanism of action affect its use in AD? In what ways could brain imaging and biomarkers improve future AD disease management? How promising do KOLs think Baxter’s Gammagrad could be as a disease-modifying AD drug? When should potential disease-modifying drugs be started in AD patients? How do KOLs think pricing and safety will shape the uptake of new AD treatments? What clinical research trends do KOLs predict for future AD therapies?
All these key questions and many more hot issues are answered and discussed within the new research study “Therapy Trends: Alzheimer's Disease - Breaking New Ground in Disease Modification” elaborated by FirstWord and recently published by Market Publishers Ltd.
Therapy Trends: Alzheimer's Disease - Breaking New Ground in Disease Modification
Published: May, 2012
Price: US$ 4.995,00
The study delivers insight from the most influential Alzheimer’s disease (AD) key opinion leaders (KOLs) to uncover how the major factors, advances and trends currently influence the AD treatment landscape, with particular focus on late-stage pipeline products, and how these could modify future AD management.
More new research studies by the publisher can be found at FirstWord page.